Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 03, 2026, titled "Zydus signs MoU with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection test (MCD) in India".
Zydus Lifesciences Limited Press Release Jul 03 2026
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced a Memorandum of Understanding with Apollo Hospitals to enhance access to the Shield™ Multi-Cancer Detection test in India. This collaboration aims to provide a blood test that screens for multiple cancer types in individuals at average risk. The Shield MCD test has received Breakthrough Device Designation from the U.S. FDA, highlighting its potential effectiveness in cancer screening. The press release emphasizes the importance of proactive healthcare and early detection in improving cancer treatment outcomes.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release May 28 2026
- Zydus Cancer Hospital, Ahmedabad marks 200+ Stereotactic Radiotherapy (SRT)/SRS for Brain Tumours
- Press Release May 19 2026
- Press Release May 06 2026
- Press Release Apr 25 2026
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Jul 23 2026
- Zydus Lifesciences Limited Press Release Aug 01 2026
- Zydus Lifesciences Limited Press Release Aug 04 2026
- Zydus Lifesciences Limited Press Release Aug 11 2026
- Zydus Hospitals Sets New Benchmarks in High-Risk Pregnancy and Complex Gynaecological Care
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences